News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
795,799 Results
Type
Article (71501)
Company Profile (171)
Press Release (724105)
Multimedia
Podcasts (194)
Webinars (31)
Section
Business (212597)
Career Advice (3389)
Deals (37735)
Drug Delivery (158)
Drug Development (87603)
Employer Resources (188)
FDA (17912)
Job Trends (16289)
News (367881)
Policy (37358)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2953)
Academic (2)
Accelerated approval (42)
Adcomms (37)
Allergies (170)
Alliances (53246)
ALS (204)
Alzheimer's disease (1862)
Antibody-drug conjugate (ADC) (398)
Approvals (18124)
Artificial intelligence (679)
Autoimmune disease (238)
Automation (50)
Bankruptcy (374)
Best Places to Work (12244)
BIOSECURE Act (23)
Biosimilars (214)
Biotechnology (110)
Bladder cancer (184)
Brain cancer (71)
Breast cancer (713)
Cancer (5515)
Cardiovascular disease (486)
Career advice (2901)
Career pathing (45)
CAR-T (320)
CDC (70)
Celiac Disease (2)
Cell therapy (882)
Cervical cancer (42)
Clinical research (74656)
Collaboration (2030)
Company closure (6)
Compensation (1273)
Complete response letters (90)
COVID-19 (2988)
CRISPR (110)
C-suite (1023)
Cystic fibrosis (156)
Data (7031)
Decentralized trials (2)
Denatured (67)
Depression (172)
Diabetes (579)
Diagnostics (7225)
Digital health (52)
Diversity (13)
Diversity, equity & inclusion (45)
Drug discovery (331)
Drug pricing (233)
Drug shortages (35)
Duchenne muscular dystrophy (283)
Earnings (87702)
Editorial (70)
Employer branding (22)
Employer resources (163)
Events (124754)
Executive appointments (1097)
FDA (21372)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (29)
Funding (1678)
Gene editing (236)
Generative AI (70)
Gene therapy (742)
GLP-1 (1177)
Government (5383)
Grass and pollen (8)
Guidances (394)
Healthcare (20454)
HIV (79)
Huntington's disease (57)
IgA nephropathy (91)
Immunology and inflammation (316)
Immuno-oncology (86)
Indications (152)
Infectious disease (3329)
Inflammatory bowel disease (222)
Inflation Reduction Act (17)
Influenza (137)
Intellectual property (276)
Interviews (646)
IPO (17406)
IRA (61)
Job creations (4383)
Job search strategy (2372)
JPM (70)
Kidney cancer (20)
Labor market (97)
Layoffs (662)
Leadership (44)
Legal (9239)
Liver cancer (102)
Longevity (28)
Lung cancer (743)
Lymphoma (410)
Machine learning (53)
Management (63)
Manufacturing (969)
MASH (191)
Medical device (14674)
Medtech (14752)
Mergers & acquisitions (21496)
Metabolic disorders (1550)
mRNA (204)
Multiple sclerosis (179)
NASH (24)
Neurodegenerative disease (421)
Neuropsychiatric disorders (113)
Neuroscience (3348)
Neurotech (1)
NextGen: Class of 2026 (7222)
Non-profit (5022)
Now hiring (41)
Obesity (760)
Opinion (350)
Ovarian cancer (180)
Pain (241)
Pancreatic cancer (258)
Parkinson's disease (357)
Partnered (36)
Patents (565)
Patient recruitment (593)
Peanut (65)
People (64947)
Pharmaceutical (45)
Pharmacy benefit managers (35)
Phase 1 (23043)
Phase 2 (32536)
Phase 3 (24573)
Pipeline (6826)
Policy (365)
Postmarket research (3223)
Preclinical (10109)
Press Release (71)
Prostate cancer (284)
Psychedelics (61)
Radiopharmaceuticals (322)
Rare diseases (1077)
Real estate (6795)
Recruiting (77)
Regulatory (27905)
Reports (59)
Research institute (2679)
Resumes & cover letters (523)
Rett syndrome (33)
RNA editing (20)
RSV (95)
Schizophrenia (168)
Series A (288)
Series B (205)
Service/supplier (14)
Sickle cell disease (111)
Special edition (29)
Spinal muscular atrophy (179)
Sponsored (51)
Startups (3843)
State (2)
Stomach cancer (21)
Supply chain (126)
Tariffs (101)
The Weekly (124)
Vaccines (1195)
Venture capital (109)
Weight loss (515)
Women's health (109)
Worklife (23)
Date
Today (138)
Last 7 days (675)
Last 30 days (3205)
Last 365 days (32057)
2026 (7479)
2025 (32212)
2024 (36768)
2023 (41668)
2022 (52930)
2021 (57694)
2020 (56553)
2019 (50045)
2018 (38059)
2017 (35469)
2016 (35799)
2015 (41373)
2014 (35528)
2013 (31394)
2012 (33196)
2011 (33228)
2010 (32288)
Location
Africa (1088)
Alabama (95)
Alaska (7)
Arizona (323)
Arkansas (15)
Asia (46700)
Australia (8074)
California (12290)
Canada (3496)
China (1270)
Colorado (524)
Connecticut (543)
Delaware (369)
Europe (108380)
Florida (1860)
Georgia (406)
Hawaii (4)
Idaho (64)
Illinois (1014)
India (82)
Indiana (568)
Iowa (23)
Japan (488)
Kansas (132)
Kentucky (47)
Louisiana (37)
Maine (85)
Maryland (1528)
Massachusetts (8901)
Michigan (374)
Minnesota (692)
Mississippi (7)
Missouri (150)
Montana (36)
Nebraska (28)
Nevada (137)
New Hampshire (90)
New Jersey (3327)
New Mexico (33)
New York (3268)
North Carolina (1651)
North Dakota (9)
Northern California (6056)
Ohio (379)
Oklahoma (24)
Oregon (44)
Pennsylvania (2445)
Puerto Rico (24)
Rhode Island (50)
South America (1488)
South Carolina (74)
South Dakota (1)
Southern California (4843)
Tennessee (199)
Texas (1933)
United States (44057)
Utah (373)
Vermont (1)
Virginia (302)
Washington D.C. (84)
Washington State (985)
West Virginia (4)
Wisconsin (131)
Wyoming (2)
795,799 Results for "crohn s and colitis foundation of america ccfa".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease
February 17, 2026
·
11 min read
Press Releases
Press Release: Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease
February 17, 2026
·
12 min read
Press Releases
Nimbus Therapeutics to Present Preclinical and Translational Data on Novel SIK2 Inhibitors at 21st Congress of European Crohn’s and Colitis Organisation (ECCO)
February 17, 2026
·
3 min read
Press Releases
Leading the Next Wave of Innovative IBD Therapeutics Targeting Immunometabolism: Josep Bassaganya-Riera Launches Clinical Program and Business Venture to Develop NIM-1324 for Ulcerative Colitis and Crohn’s disease
February 17, 2026
·
5 min read
Funding
Teva Bags $400M Backing From Blackstone To Advance Sanofi-Partnered Drug
The funding comes weeks after TL1A blocker duvakitug maintained clinical remission rates above 50% in patients with ulcerative colitis and Crohn’s disease in a Phase 2b trial.
March 4, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Stoked Bio Secures Exclusive Global License to Develop a Promising New Therapy for Crohn’s Disease
February 18, 2026
·
3 min read
Immunology and inflammation
Lilly Eyes Pipeline in a Product as GLP-1s Move Into I&I
In addition to claiming revenue of $19.3 billion for the fourth quarter, Eli Lilly executives offered a glimpse into their strategy to expand their GLP-1 franchise into the immunology and inflammation space, with trials currently underway in asthma, psoriatic arthritis, Crohn’s disease and ulcerative colitis.
February 4, 2026
·
2 min read
·
Heather McKenzie
BioMidwest
Geneoscopy to Present Research on Inflammatory Bowel Disease at Crohn’s & Colitis Foundation’s IBD Innovate 2024 Conference
Geneoscopy, Inc. will present research at the Crohn’s & Colitis Foundation’s IBD Innovate 2024 Conference in Cambridge, Mass., April 9-10.
April 3, 2024
·
2 min read
Press Releases
Avobis Bio Announces Expanded Primary Analysis Results from the Randomized Multicenter STOMP2 Clinical Trial to be Presented at European Crohn’s and Colitis Organisation (ECCO) Congress
January 30, 2026
·
4 min read
Business
Azenta Announces Collaboration with the Crohn’s & Colitis Foundation to Support its Crohn’s Disease and Ulcerative Colitis Clinical Research
Azenta, Inc. (Nasdaq: AZTA) today announced it has been selected by the Crohn’s & Colitis Foundation (the “Foundation”) as its sample management services provider for two of its large-scale prospective research cohorts, CAPTURE IBD and IBD SIRQC, which investigate pediatric and surgical care for Crohn’s disease and ulcerative colitis.
June 4, 2024
·
4 min read
1 of 79,580
Next
